Fri, Nov 20, 2026中文About
Filings today 284 / Covered 15
Source: TDnet timely disclosures
Updated 11/20 20:30M&A / TOB 20 Guidance 7 Buybacks 11 Dividends 4 Capital 12 Earnings 16 People 3

Modalis completes exercise of 19th series warrants, issuing 4.38 million shares in Nov.

Wed, Nov 18, 2026 16:40 JST Modalis Therapeutics Corporation (4883.T) Pharmaceutical 中文

Modalis Therapeutics Corporation (4883), listed on the Tokyo Stock Exchange Growth market, said on Nov. 18 that EVO FUND exercised its remaining 19th series moving-strike warrants between Nov. 2 and Nov. 18, 2026, with 4.38 million new shares delivered in November and no warrants left outstanding.

Shares delivered in November4.38 million shares
Warrants exercised in November43,800 units (18.3% of total issued)
Exercise price¥28.0
Unexercised warrants0 units (0 shares)

The 19th series warrants were issued on June 12, 2026 through a third-party allotment to EVO FUND, with 240,000 units issued in total. The 43,800 units exercised in November represent 18.3% of the total and equal the entire balance unexercised at the end of October.

All November exercises took place on three days at an exercise price of ¥28.0:

DateNew sharesUnits exercised
Nov. 10100,0001,000
Nov. 131,700,00017,000
Nov. 182,580,00025,800

All shares delivered were newly issued; no treasury shares were used. The daily exercise price, adjusted under the moving-strike clause, ranged between ¥28.0 and ¥30.0 during the period.

Shares outstanding at the end of October stood at 115,954,098, including 64 treasury shares. Under Article 434 of the TSE listing regulations, the 4.38 million shares delivered amount to 4.5% of the 96,334,098 shares listed as of the warrants' payment date.

The company referred investors to its May 27, 2026 announcement on the issuance of the 19th series warrants and its 2nd series unsecured private-placement bonds for further details.


Original filings
Related